دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Transcatheter Mitral Valve Replacement: An Update on Current Techniques, Technologies, and Future Directions
MarkHenseyMB, BCh, BAOaRichard A.BrownMDbSudishLalMBChB, BPharmcJanarthananSathananthanMBChBdJianYeMDdAnsonCheungMDdPhilippBlankeMDdJonathonLeipsicMDdRobertMossMDdRobertBooneMDdJohn G.Webbd
doi : 10.1016/j.jcin.2020.12.038
Volume 14, Issue 5, 8 March 2021, Pages 489-500
Transfemoral Transcatheter Tricuspid Valve Replacement With the EVOQUE System: A Multicenter, Observational, First-in-Human Experience
Neil P.FamMD, MSca?Ralph Stephanvon BardelebenMDb?MarkHenseyMB BCh, BAOcSusheel K.KodaliMDdRobert L.SmithMDeJ?rgHausleiterMDfgGeraldineOngMDaRobertBooneMDcTobiasRufMDbIsaacGeorgeMDdMollySzerlipMDeMichaelN?bauerMDfgFaeez M.AliMDaRobertMossMDcVinayakBapatMDdKatharinaSchnitzlerMDbFelixKreidelMDbJianYeMDc…John G.WebbMDc
doi : 10.1016/j.jcin.2020.11.045
Volume 14, Issue 5, 8 March 2021, Pages 501-511
The purpose of this observational first-in-human experience was to investigate the feasibility and safety of the EVOQUE tricuspid valve replacement system and its impact on short-term clinical outcomes.
Transcatheter Treatment Options for Severe Tricuspid Regurgitation: And the Winner Is Valve Replacement??
Gilles D.DreyfusMD, PhDaBenjaminEssayaghMDb
doi : 10.1016/j.jcin.2021.01.012
Volume 14, Issue 5, 8 March 2021, Pages 512-514
Randomized Evaluation of TriGuard 3 Cerebral Embolic Protection After Transcatheter Aortic Valve Replacement: REFLECT II
TamimM.NazifMDaJeffreyMosesMDaRahulSharmaMDcAbhijeetDhobleMDbJoshuaRovinMDdDavidBrownMDePhilipHorwitzMDfRajendraMakkarMDgRobertStolerMDhJohnForrestMDiStevenMesséMDjSarahDickermanBSciJosephBrennanMDiRobertZivadinovMDkMichael G.DwyerMDkAlexandra J.LanskyMDilREFLECT II Trial Investigators
doi : 10.1016/j.jcin.2020.11.011
Volume 14, Issue 5, 8 March 2021, Pages 515-527
The REFLECT II (Randomized Evaluation of TriGuard 3 Cerebral Embolic Protection After Transcatheter Aortic Valve Implantation) trial was designed to investigate the safety and efficacy of the TriGUARD 3 (TG3) cerebral embolic protection in patients undergoing transcatheter aortic valve replacement.
Reflections on the Fate of Cerebral Embolic Protection Devices With TAVR: The REFLECT II Trial?
Nicolas M.Van MieghemMD, PhDJoostDaemenMD, PhD
doi : 10.1016/j.jcin.2020.12.021
Volume 14, Issue 5, 8 March 2021, Pages 528-530
no abstract
Online Quantitative Aortographic Assessment of Aortic Regurgitation After TAVR: Results of the OVAL Study
RodrigoModoloMDabc?Martijnvan MourikPhDa?AbdelhakEl BouzianiMDa?HideyukiKawashimaMDadLiesbethRosseelMDdMohammadAbdelghaniMD, PhDaeJean-PaulAbenMScfTristanSlotsBScfCherifSahyounPhDgJanBaanMD, PhDaJose P.S.HenriquesMD, PhDaKarel T.KochMD, PhDaMarijeVisMD, PhDaOsamaSolimanMD, PhDdYoshinobuOnumaMD, PhDdJoannaWykrzykowskaMD, PhDaRobbertde WinterMD, PhDaPatrick W.SerruysMD, PhDdh
doi : 10.1016/j.jcin.2020.11.014
Volume 14, Issue 5, 8 March 2021, Pages 531-538
The aim of this study was to investigate the online assessment feasibility of aortography using videodensitometry in the catheterization laboratory during transcatheter aortic valve replacement (TAVR).
Online Quantitative Aortography Assessment of Aortic Regurgitation After TAVR: Let There Be Light Among Shades of Grey?
NicolasDumonteilMD
doi : 10.1016/j.jcin.2020.12.022
Volume 14, Issue 5, 8 March 2021, Pages 539-540
Tip-to-Base LAMPOON for Transcatheter Mitral Valve Replacement With a Protected Mitral Annulus
John C.LiskoMD, MPHa?Vasilis C.BabaliarosMDa?Jaffar M.KhanMDbNorihikoKamiokaMDaPatrick T.GleasonMDaGaetanoPaoneMDaIsidaBykuMDaJasleenTiwanaMDbJames M.McCabeMDcKrishnaCherukuriMDdRamziKhalilMDdDavidLasordaDOdSachin S.GoelMDeNeal S.KleimanMDeMichael J.ReardonMDeDavid V.DanielsMDfChristianSpiesMDfPaulMahoneyBS, MDg…Adam B.GreenbaumMDa†
doi : 10.1016/j.jcin.2020.11.034
Volume 14, Issue 5, 8 March 2021, Pages 541-550
The purpose of this study was to evaluate tip-to-base intentional laceration of the anterior mitral leaflet to prevent left ventricular outflow tract obstruction (LAMPOON) in patients undergoing transcatheter mitral valve replacement (TMVR) in annuloplasty rings or surgical mitral valves.
The Multiple Faces of LAMPOON?
MohamedAbdel-WahabMDaDavidHolzheyMDb
doi : 10.1016/j.jcin.2020.12.031
Volume 14, Issue 5, 8 March 2021, Pages 551-553
Association of Hospital Procedural Volume With Outcomes of Percutaneous Left Atrial Appendage Occlusion
SalikNazirMDa?Keerat RaiAhujaMDb?DhavalKolteMD, PhDcToshiakiIsogaiMD, MPHdNobuakiMichihataMD, MPH, PhDeAnas M.SaadMDdP. KasiRamanathanMDfAmarKrishnaswamyMDdOussama M.WazniMDdWalid I.SalibaMDdRajeshGuptaMDaSamir R.KapadiaMDd
doi : 10.1016/j.jcin.2020.11.029
Volume 14, Issue 5, 8 March 2021, Pages 554-561
The aim of this study was to examine the association between percutaneous left atrial appendage occlusion (LAAO) procedural volume and in-hospital outcomes.
Unraveling the Gordian Knot!: Hospital Volume Threshold to Optimize Outcomes After Left Atrial Appendage Occlusion?
Issam D.MoussaMD, MBAabRandall J.LeeMD, PhDc
doi : 10.1016/j.jcin.2021.01.011
Volume 14, Issue 5, 8 March 2021, Pages 562-565
Long-Term Outcomes After Atrial Septal Defect Transcatheter Closure by Age and Against Population Controls
LusineAbrahamyanMD, MPH, PhDabcChristofferDharmaMScdSamiAlnasserMDeJimingFangMSc, PhDdPeter C.AustinPhDdDouglas S.LeeMD, PhDdfMarkOstenMDgEric M.HorlickMDCMg
doi : 10.1016/j.jcin.2020.12.029
Volume 14, Issue 5, 8 March 2021, Pages 566-575
The long-term outcomes after transcatheter closure of atrial septal defects (ASD) in adults are reported and compared between age groups and against population control patients.
Atrial Septal Defect: Transcatheter Closure Is Not Bad, But There Is More to the Story?
LarryLatsonMDDavidBristonMD
doi : 10.1016/j.jcin.2021.01.008
Volume 14, Issue 5, 8 March 2021, Pages 576-577
Balloon-Assisted BASILICA to Facilitate Redo TAVR
Adam B.GreenbaumMDaNorihikoKamiokaMDaJohn P.VavalleMDbJohn C.LiskoMD, MPHaPatrick T.GleasonMDaGaetanoPaoneMDcKendra J.GrubbMD, MHAcChristopher G.BruceMB ChBdRobert J.LedermanMDdVasilis C.BabaliarosMDa
doi : 10.1016/j.jcin.2020.10.056
Volume 14, Issue 5, 8 March 2021, Pages 578-580
Left-Sided Venous Access: A Technique to Simplify and Improve Success of Tricuspid Valve Clip Repair
LukeOakleyMDSung-HanYoonMDMoodyMakarMDAaronYungMDDhairyaPatelMPHNavjotSekhonMDMamooNakamuraMDTarunChakravartyMDRaj R.MakkarMD
doi : 10.1016/j.jcin.2020.11.044
Volume 14, Issue 5, 8 March 2021, Pages 581-582
Pulsatile Femoral Veins Due to Severe Tricuspid Regurgitation
FlorianReyMDQuentinChatelainMD
doi : 10.1016/j.jcin.2020.11.033
Volume 14, Issue 5, 8 March 2021, Pages e43-e44
Percutaneous Thromboembolectomy in a High-Risk Surgical Patient With Thrombus Straddling a Patent Foramen Ovale
DeannaGillMDaSeanEvansBSaMatthew T.BrownMDaAnanthVaddeMDbRonaldChangMDcMatthew D.StanleyMDdMaanJokhadarMDeWendy R.GreeneMDdWilliam D.JordanJr.MDcWilliam B.KeelingMDf
doi : 10.1016/j.jcin.2020.11.041
Volume 14, Issue 5, 8 March 2021, Pages e45-e47
Cardiac Tamponade Due to Very Late Perforation of Left Atrium by Atrial Septal Defect Occluder
PavlosTsinivizovMDaAndreasGiannakopoulosMDaDimitrisVarvarousisMDaNikolaosMichelinakisMDaNikolasKoumallosMDbAthanasios J.ManolisMDa
doi : 10.1016/j.jcin.2020.11.039
Volume 14, Issue 5, 8 March 2021, Pages e49-e51
Shouldn’t Patients With Paradoxical Emboli and Thrombophilia Be Given Anticoagulant Agents?
M. RezaAzarpazhoohMDChrysiBogiatziMSc, MDJ. DavidSpenceMD
doi : 10.1016/j.jcin.2020.12.024
Volume 14, Issue 5, 8 March 2021, Page 583
Reply: Shouldn’t Patients With Paradoxical Emboli and Thrombophilia Be Given Anticoagulant Agents?
KaiLiuMD, PhD†BoSongMD, PhD†Igor F.PalaciosMDIgnacioInglessis-AzuajeMDEng H.LoPhDYuMingXuMD, PhD‡Ferdinando S.BuonannoMD‡MingMingNingMD‡
doi : 10.1016/j.jcin.2021.01.002
Volume 14, Issue 5, 8 March 2021, Pages 583-584
Transcatheter Repair for Tricuspid Regurgitation: Ready or Not?
JulienTernacleMD, PhDWalidBen AliMD, PhDThomasModineMD, PhD
doi : 10.1016/j.jcin.2020.12.036
Volume 14, Issue 5, 8 March 2021, Pages 584-585
Reply: Transcatheter Repair for Tricuspid Regurgitation: Ready or Not?
ClaudioMontaltoMDAlessandroSticchiMDArif A.KhokharBM BChAzeemLatibMDAntonioMangieriMD
doi : 10.1016/j.jcin.2021.01.013
Volume 14, Issue 5, 8 March 2021, Pages 585-586
Long-Term Durability of the Next-Generation Acurate neo 2 Transcatheter Heart Valve: Insights From Bench Testing to 25 Years
JanarthananSathananthanMBChB, MPHUriLandesMDLionelFlactionPhDArnaudHumairMScStéphaneDelaloyePhDStefanToggweilerMDLarsS?ndergaardMD, DMScDavid A.WoodMDJohn G.WebbMD
doi : 10.1016/j.jcin.2020.10.030
Volume 14, Issue 5, 8 March 2021, Pages 586-588
Prevalence and Impact of Post-Procedural Delirium After Percutaneous Repair of Mitral and Tricuspid Valves
Maria I.K?rberMD†MatthieuSch?fer†RakaveVimalathasanVictorMauriMDChristosIliadisMDClemensMetzeMDHenrik tenFreyhausMDVolkerRudolphMDStephanBaldusMDRomanPfisterMD
doi : 10.1016/j.jcin.2020.11.031
Volume 14, Issue 5, 8 March 2021, Pages 588-590
Combined Procedure of Percutaneous Mitral Valve Repair and Left Atrial Appendage Occlusion: A Multicenter Study
GianpieroD’AmicoMDRodrigoEstèvez-LoureiroMD, PhDXavier FreixaRofastesMD, PhDFedericoRoncoMDLuisNombela-FrancoMD, PhDBrunoMelicaMDFrancescoBedogniMDFrancescoSaiaMD, PhDIgnacioCruz-GonzalezMD, PhDGiuseppeTarantiniMD, PhD
doi : 10.1016/j.jcin.2020.11.030
Volume 14, Issue 5, 8 March 2021, Pages 590-592
